Abstract
Treatment of acute myeloid leukemia (AML) is still a challenge because of common relapses or resistance to treatment. Therefore, the development of new therapeutic approaches is necessary. Various studies have shown that certain cancers, including some chemoresistant AML subsets, have upregulated oxidative phosphorylation. In this study, we aimed to assess treatment-resistant AML patients' cell modulation using oxidative phosphorylation inhibitors metformin and atovaquone alone and in various combinations with cytosine analog cytarabine and apoptosis inducer venetoclax. Metabolic activity analysis using Agilent Seahorse XF Extracellular Flux Analyzer revealed that peripheral blood mononuclear cells' metabolic state was different among treatment-resistant AML patients. We demonstrated that metformin decreased therapy-resistant-AML cell oxidative phosphorylation ex vivo, cotreatment with cytarabine and venetoclax slightly increased the effect. However, treatment with atovaquone did not have a marked effect in our experiment. Cell treatment had a slight effect on cell proliferation inhibition; combination of metformin, cytarabine, and venetoclax had the strongest effect. Moreover, a slightly higher effect on cell proliferation and...Continue Reading
References
Apr 21, 2009·Nature Methods·Jacek R WiśniewskiMatthias Mann
Oct 23, 2010·Expert Opinion on Drug Delivery·Bhupender S Chhikara, Keykavous Parang
Mar 19, 2011·Cancer Research·Dimitrios IliopoulosKevin Struhl
Nov 19, 2011·Cancer Cell·Marko SkrtićAaron D Schimmer
Feb 19, 2013·Cancer Cell·Francisca VazquezPere Puigserver
Dec 18, 2013·Nature Methods·Ute DistlerStefan Tenzer
May 21, 2014·ELife·William W WheatonNavdeep S Chandel
Dec 18, 2014·Nature Chemical Biology·Samuel E Weinberg, Navdeep S Chandel
May 10, 2015·Cancer Chemotherapy and Pharmacology·Sam BrondfieldScott C Kogan
Jun 18, 2015·Cancers·Yi-Ju WuJun-Yang Liou
Aug 19, 2015·Seminars in Cell & Developmental Biology·Annie L HsiehChi V Dang
Sep 1, 2015·Oncotarget·Kaiyu YuanYabing Chen
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Nov 14, 2015·Molecular Diversity·Hasitha Shilpa AnantarajuPerumal Yogeeswari
Nov 26, 2015·Biochimica Et Biophysica Acta·Marija GerMindaugas Valius
Apr 28, 2016·Cancer Chemotherapy and Pharmacology·Hui-Hui Zhang, Xiu-Li Guo
May 4, 2016·Oncotarget·Marco FiorilloMichael P Lisanti
May 20, 2016·Molecular Cancer Therapeutics·Zheqiong TanYa Cao
Jul 28, 2016·Nature Communications·Thomas M AshtonWilliam Gillies McKenna
Oct 19, 2016·British Journal of Clinical Pharmacology·Darcy Bates, Alan Eastman
Dec 16, 2016·International Journal of Molecular Sciences·Armin ZebischHeinz Sill
Jan 23, 2017·Critical Reviews in Oncology/hematology·Gevorg TamamyanMarina Konopleva
Apr 19, 2017·Cancer Discovery·Thomas FargeJean-Emmanuel Sarry
Oct 21, 2017·Blood·Andrew H Wei, Ing S Tiong
Jan 27, 2018·Hereditas·Qiong-Ni ZhuYing Guo
Apr 25, 2018·Journal of Bioenergetics and Biomembranes·Zhuo LvYin He
Citations
Apr 23, 2020·Frontiers in Oncology·Svetlana B PaninaNatalia V Kirienko
Jan 8, 2021·Frontiers in Oncology·Alessandro BarbatoAlessandra Romano
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Giedrė ValiulienėRūta Navakauskienė
Oct 19, 2021·Frontiers in Genetics·Chao DongLijun Zhang